Ligandal is reportedly the only company developing a prospective “antidote” and vaccine in a single platform for COVID-19, with an approach that could actually help eliminate the virus from an already-infected host, while also bolstering the immune response.

Following close on the heels of the company’s vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.